Tags

Type your tag names separated by a space and hit enter

Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis.
Am J Vet Res. 2009 Feb; 70(2):210-5.AJ

Abstract

OBJECTIVE

To assess the clinical, biochemical, and histologic effects of topically administered diclofenac liposomal cream (DLC) in the treatment of horses with experimentally induced osteoarthritis.

ANIMALS

24 horses.

PROCEDURES

Osteoarthritis was induced arthroscopically in 1 middle carpal joint of all horses. Eight horses treated with DLC were given 7.3 g twice daily via topical application. Eight horses treated with phenylbutazone were given 2 g orally once daily. Eight control horses received no treatment. Evaluations included clinical, radiographic, magnetic resonance imaging, synovial fluid, gross, and histologic examinations as well as histochemical and biochemical analyses.

RESULTS

No adverse treatment-related events were detected. Horses that were treated with DLC or phenylbutazone had significant clinical improvement of lameness, unlike the control horses. Treatment with DLC induced significant improvement in staining and total articular glycosaminoglycan content, compared with no treatment. Treatment with phenylbutazone induced significant reduction in synovial fluid prostaglandin E2 concentration, compared with DLC and no treatment. Treatment with DLC induced significantly less radial carpal bone sclerosis and overall gross cartilage erosion, compared with phenylbutazone.

CONCLUSIONS AND CLINICAL RELEVANCE

Results indicated that DLC had both clinical sign-modifying and disease-modifying effects. Only clinical sign-modifying effects were detected in association with phenylbutazone administration. Treatment with DLC had significant beneficial effects, compared with phenylbutazone, and no detrimental effects. Results suggested that DLC is a viable therapeutic option for horses with osteoarthritis.

Authors+Show Affiliations

Gail Holmes Equine Orthopaedic Research Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19231953

Citation

Frisbie, David D., et al. "Evaluation of Topically Administered Diclofenac Liposomal Cream for Treatment of Horses With Experimentally Induced Osteoarthritis." American Journal of Veterinary Research, vol. 70, no. 2, 2009, pp. 210-5.
Frisbie DD, McIlwraith CW, Kawcak CE, et al. Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res. 2009;70(2):210-5.
Frisbie, D. D., McIlwraith, C. W., Kawcak, C. E., Werpy, N. M., & Pearce, G. L. (2009). Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis. American Journal of Veterinary Research, 70(2), 210-5. https://doi.org/10.2460/ajvr.70.2.210
Frisbie DD, et al. Evaluation of Topically Administered Diclofenac Liposomal Cream for Treatment of Horses With Experimentally Induced Osteoarthritis. Am J Vet Res. 2009;70(2):210-5. PubMed PMID: 19231953.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis. AU - Frisbie,David D, AU - McIlwraith,C Wayne, AU - Kawcak,Chris E, AU - Werpy,Natasha M, AU - Pearce,Gregory L, PY - 2009/2/24/entrez PY - 2009/2/24/pubmed PY - 2009/4/1/medline SP - 210 EP - 5 JF - American journal of veterinary research JO - Am. J. Vet. Res. VL - 70 IS - 2 N2 - OBJECTIVE: To assess the clinical, biochemical, and histologic effects of topically administered diclofenac liposomal cream (DLC) in the treatment of horses with experimentally induced osteoarthritis. ANIMALS: 24 horses. PROCEDURES: Osteoarthritis was induced arthroscopically in 1 middle carpal joint of all horses. Eight horses treated with DLC were given 7.3 g twice daily via topical application. Eight horses treated with phenylbutazone were given 2 g orally once daily. Eight control horses received no treatment. Evaluations included clinical, radiographic, magnetic resonance imaging, synovial fluid, gross, and histologic examinations as well as histochemical and biochemical analyses. RESULTS: No adverse treatment-related events were detected. Horses that were treated with DLC or phenylbutazone had significant clinical improvement of lameness, unlike the control horses. Treatment with DLC induced significant improvement in staining and total articular glycosaminoglycan content, compared with no treatment. Treatment with phenylbutazone induced significant reduction in synovial fluid prostaglandin E2 concentration, compared with DLC and no treatment. Treatment with DLC induced significantly less radial carpal bone sclerosis and overall gross cartilage erosion, compared with phenylbutazone. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that DLC had both clinical sign-modifying and disease-modifying effects. Only clinical sign-modifying effects were detected in association with phenylbutazone administration. Treatment with DLC had significant beneficial effects, compared with phenylbutazone, and no detrimental effects. Results suggested that DLC is a viable therapeutic option for horses with osteoarthritis. SN - 0002-9645 UR - https://www.unboundmedicine.com/medline/citation/19231953/Evaluation_of_topically_administered_diclofenac_liposomal_cream_for_treatment_of_horses_with_experimentally_induced_osteoarthritis_ L2 - http://avmajournals.avma.org/doi/full/10.2460/ajvr.70.2.210?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -